Track topics on Twitter Track topics that are important to you
480 Armand-Frappier Blvd
Phone: (450) 686-1017 or 1 888 686-1017
Fax: (450) 686-9141
Joint Venture agreed to market Oleptro in the US
A look at today's forthcoming news stories:Dendreon's Provenge, a first of a kind prostate cancer treatment, wins FDA approval; a raft of Q1 results came out this week, painting a positive financial p...
To determine whether the test product, Labopharm Tramadol HCl Once-A-Day (OAD) 200 mg film-coated tablets, and the reference product, Labopharm Tramadol HCl OAD 200 mg uncoated tablets, ar...
The purposes of this study were: - To evaluate the plasma pharmacokinetic profile of tramadol and its principal metabolite, the O-desmethyltramadol, after a single oral administra...
The main purpose of this study is to compare the pharmacokinetic profile to establish the better controlled liberation of the test product (Tramadol HCL OAD tablets of 200 mg, Labopharm) a...
For the purpose of marketing OLEPTRO(TM) in the United States, Angelini and Labopharm established the joint venture Angelini Labopharm, which is equally owned by both companies. This partnership leve...
For the purpose of marketing OLEPTRO(TM) in the United States, Gruppo Angelini and Labopharm established the joint venture Angelini Labopharm, which is equally owned by affiliates of both companies. T...
We are an emerging leader in optimizing the performance of existing small molecule drugs using our proprietary controlled-release technologies. Our lead product, a unique once-daily formulation of tra...
We have published hundreds of Labopharm news stories on BioPortfolio along with dozens of Labopharm Clinical Trials and PubMed Articles about Labopharm for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Labopharm Companies in our database. You can also find out about relevant Labopharm Drugs and Medications on this site too.